Antiviral Therapy and the Role of Ccc Dna in Persistent Hbv Infection

The main aim of treatment for chronic hepatitis B is to suppress hepatitis B virus (HBV) replication before there is irreversible liver damage. Currently, interferonα (IFN-α) is the only approved treatment for chronic hepatitis B. However, it has limited efficacy, is expensive and is associated with many unpleasant side-effects. In the last 5 years, several new antiviral agents have shown promise in the treatment of chronic hepatitis B, but long-term treatment is needed for sustained antiviral effects. Unfortunately, drug-resistant mutants have been found in some patients who have been on treatment for long durations (> 6 months). The incidence, clinical outcome and biological significance of these mutants will be reviewed.